checkAd

    DGAP-Adhoc  664  0 Kommentare Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc





    DGAP-Ad-hoc: Biotest AG / Key word(s): Disposal


    Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc


    23-Jan-2017 / 13:00 CET/CEST


    Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.


    The issuer is solely responsible for the content of this announcement.



    Ad-hoc RELEASE

    Announcement according to Article 17 European Market Abuse Regulation (MAR)


    Biotest to sell US therapy business to ADMA Biologics, Inc. receiving
    approximately 50% of the shares of ADMA Biologics, Inc

    Dreieich, 23 January 2017. Biotest's US subsidiary, Biotest Pharmaceuticals
    Corporation, Boca Raton, Florida, USA, (BPC), has entered into a definitive
    agreement with ADMA Biologics, Inc., Ramsey, New Jersey, USA, (ADMA) to
    sell certain assets of the US therapy business. Included in the assets to
    be transferred at closing are BPC's plasma fractionation facility, its
    commercial products, contract manufacturing agreements as well as BPC's
    Boca Raton, Florida headquarters and real properties.

    Upon closing of this transaction, Biotest will receive equity interest in
    ADMA's issued and outstanding capital stock in the form of 50% minus one
    share representing 25% of the voting rights. In addition, Biotest will:
    - Receive two ADMA plasma centers in the USA on January 1, 2019

    - Obtain distribution rights for ADMA's innovative product (RI-002) and a
    right of first offer for the distribution of future ADMA developed
    plasma-based products in Europe, Near and Middle East and selected
    Asian countries

    - Participate from the future development of products in the USA

    As part of the transaction, Biotest will contribute EUR11.5 million in cash
    as well as a EUR14 million loan. The loan bears 6% interest and has a term
    of 5 years. In addition, Biotest will contribute up to EUR11.5 million
    towards a future capital increase of ADMA on equal terms as third party
    investors.

    BPC will maintain its focus on its plasma operations business which
    includes 22 plasma centers located across the USA.

    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc DGAP-Ad-hoc: Biotest AG / Key word(s): Disposal Biotest AG: Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc 23-Jan-2017 / 13:00 CET/CEST Disclosure of an inside …

    Schreibe Deinen Kommentar

    Disclaimer